Affiliation:
1. Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine , Lianyungang 222000 , China
2. Department of Acupuncture, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine , Lianyungang 222000 , China
3. Department of Pharmacy, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine , No.160 Chaoyang Middle Road , Haizhou District , Lianyungang 222000 , China
Abstract
Abstract
Currently, the effect and molecular mechanism of calycosin, the main active ingredient of Qinshi Simiao San, which can alleviate chronic prostatitis (CP), on CP remain unclear. This study aimed to elucidate the potential mechanism of action of calycosin in CP in a rat CP model. The prostate tissue morphology was evaluated based on hematoxylin–eosin staining. Enzyme-linked immunosorbent assay was conducted to evaluate inflammatory cytokine and immune factor levels (secretory immunoglobulin A [SIgA]; immunoglobulin G [IgG]) in prostate tissues and serum. Additionally, representative biomarkers of oxidative stress, including malondialdehyde, superoxide dismutase, and catalase were detected using detection kits, and reactive oxygen species release was evaluated using immunofluorescence staining. Furthermore, the p38 mitogen-activated protein kinase (p38MAPK)/NF-kappaB (NF-κB) signaling pathway was analyzed by western blotting. The results showed that calycosin substantially ameliorated the pathological damage to prostate tissues of the CP rats. Moreover, calycosin significantly downregulated interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha, IgG, and SIgA levels. Furthermore, we found that calycosin considerably suppressed oxidative stress and inhibited the activation of the p38MAPK/NF-κB signaling pathway in rats with CP. In summary, our findings revealed that calycosin protects against CP in rats by inhibiting the p38MAPK/NF-κB pathway.
Reference32 articles.
1. Zhao B, Zheng J, Qiao Y, Wang Y, Luo Y, Zhang D, et al. Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis. Transl Androl Urol. 2021;10:1976–87. 10.21037/tau-21-139.
2. Pirola GM, Verdacchi T, Rosadi S, Annino F, De Angelis M. Chronic prostatitis: current treatment options. Res Rep Urol. 2019;11:165–74. 10.2147/RRU.S194679.
3. Allen S. The vascular factor plays the main role in the cause of pain in men with chronic prostatitis and chronic pelvic pain syndrome: The results of clinical trial on thermobalancing therapy. Diseases. 2017;5(4):25. 10.3390/diseases5040025.
4. Gong QK, Huang XF, Chen Y, Xue JG. [Acupuncture therapy for chronic prostatitis/chronic pelvic pain syndrome and its central neural mechanisms]. Zhonghua Nan Ke Xue. 2020;26:559–63.
5. Lin D, Zhang M, Luo C, Wei P, Cui K, Chen Z. Targeting ferroptosis attenuates inflammation, fibrosis, and mast cell activation in chronic prostatitis. J Immunol Res. 2022;2022:6833867. 10.1155/2022/6833867.